Japan has been at the forefront of regenerative medicine research for a number of years, partly due to the fact that its population is rapidly aging (and declining too). The country is also at the forefront of robotics related research for similar reasons. Here is a 2013 article from Japan that projects stellar growth in the local and world market for regenerative medicine.
One the country’s foremost scientists, Dr. Shinya Yamanaka (together with the keratinacious Dr. John Gurdon), received a Nobel Prize in 2012 for his discovery on how to transform ordinary adult skin cells into cells that act like embryonic stem cells and can then develop into virtually any other type of cell in the body. Dr. Yamanaka called these cells induced pluripotent stem cells, or iPS cells.
What does all this mean when it comes hair loss research?
It looks like time consuming stage III clinical trials that we see in the US will essentially be skipped in Japan. This is excellent news, especially since Shiseido (Japan) will be starting stage II clinical trials of Replicel (Canada)’s RHC-01 product in the first half of 2015. These trials will last for one year, and it is therefore even possible that Shiseido can bring this product to market in Japan as early as 2017 (assuming the stage II trials show good results). This is a best case scenario of course.
Japan is holding the important BioJapan 2014 World Business Forum this coming week, and Replicel is scheduled to present there on October 15, 2014. More importantly, Replicel’s team “will be meeting with Shiseido to discuss progress on their RCH-01 clinical trial and to view their purpose-built facility on Kobe Island.”
I have mentioned this a few times before on this blog, and am getting even more convinced that we in the west will have to travel to Asia when the treatment finally arrives, even if it is based on western technology!
Also see Seeking Alpha’s October 10, 2014 write-up on Replicel stock. FYI — I do not own any REPCF stock and am not advising readers on buying or selling it. I have zero expertise in the finance or biotech industries.